Navigation Links
Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
Date:3/5/2008

LOS ANGELES, March 5 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.52 price target on Inovio Biomedical Corporation (Amex: INO). "Inovio has compelling pre-clinical and clinical data regarding the ability of their technology to significantly enhance the potency of DNA vaccines, with positive interim human results from three independent clinical studies. The company's technology is further validated from license agreements with two of the world's big five vaccine companies, Merck and Wyeth, plus multiple other partnerships and collaborations," said Ross Silver, Director of Research for Vista Partners. For more information and to download the report, please visit the Vista Partners website at http://www.vistap.com.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Inovio Biomedical Corporation:

Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based immunotherapies. Inovio is a leader in developing
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Provista Awards Agreement to Spheris
5. Synvista Therapeutics to be Featured on Wallst.net
6. Synvista Therapeutics to Present at the BIO InvestorForum 2007
7. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
8. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
9. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
10. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
11. DW Healthcare Partners Announces the Sale of Tandem Labs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2008).... 28 /- Truman Medical Centers (TMC),...ates to install the,Siemens SOMATOM Definition AS ...canner is a highly adaptive scanner, providing exc...sure to the patient., "To be one of the first med..., first of its kind, state-of-the-art technology c...
(Date:8/28/2008)...28 /- Barr Pharmaceuticals,...diary, Barr Laboratories,Inc., received final app...A) to manufacture and market a generic version of ...drobromide), 4 mg, 8 mg and 12 mg tablets. Barr,in...ct immediately., Barr filed an Abbreviated New Dr...
(Date:8/28/2008)...st 28 /- ThromboGenics NV,(...ocused on innovative,treatments for eye disease, v...iness update and its financial results for the six...irst half of 2008, ThromboGenics has achieved a nu...ompany to successfully pursue the,next stage of it...
(Date:8/28/2008)... CoreValve ( www.corevalve.com ) announced today t...uation of its proprietary percutaneous ReValving S...mounted in a self-expanding frame, was initiated l...f. (Business Wire EON) August 28, 2008 -- The fir...ystem were performed in two days by John Ormiston,...
Breaking Biology Technology:Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the World's First Adaptive 128-slice CT Scanner 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 3Barr Receives Approval for Generic Version of Razadyne(R) Tablets 4Barr Receives Approval for Generic Version of Razadyne(R) Tablets 5ThromboGenics Announces Half Year Results 2008 2ThromboGenics Announces Half Year Results 2008 3ThromboGenics Announces Half Year Results 2008 4ThromboGenics Announces Half Year Results 2008 5 CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries 2
...decidedly hostile environment, the lowly tapeworm ...re of its intestinal home. , ,Capitalizing on that...of Wisconsin-Madison believe they may have found a...stine, making them more effective in their deliver...ective treatment, but also of lowering dosage and ...
..., then a second-year MBA in the University of Wisc.... Steven Burrill Technology Business Plan Competit...the prospect of winning $10,000 - though the money...ealization that this was a chance to fulfill one o...in Romania, I always wanted to be in a real busine...
... Im asked is, Why wont angels invest in my busines...apply to 90+% of the entrepreneurs asking this que...e for the vast majority of entrepreneurs though i...mon answer is the one they fear, and where relevan...angel networks , ,First, consider that the majori...
...cently began requiring applicants to pay significa...n with new medical devices and biologics. Such use...plications, and now also are required for applicat...user fees enable FDA to speed up application revie...ficant financial burden on many Wisconsin companie...
Other Biology Technology:Tapeworm's Chemical Trick Could Make Drugs More Effective 2Romanian Student Leverages Burrill Competition to Accomplish Her Dream 2Romanian Student Leverages Burrill Competition to Accomplish Her Dream 3What Angel Networks Want 2What Angel Networks Want 3What Angel Networks Want 4What Angel Networks Want 5Fast Track: FDA User Fees: Do Faster Review Times Justify the Financial Burden? 2
(Date:8/28/2008)...and and South Africa have created a biophysical me...ts, and potentially remedy even substantial hearin...unctioning regions of the ear to recognize frequen...ails are published August 29th in the open-access ...loss is an increasingly important problem in socie...
(Date:8/28/2008)...ting new research about national, home and busines...blished by a University of Houston professor and h... research community when it comes to surveillance....l be at the fifth annual Institute of Electrical a...on Advanced Video and Signal-Based Surveillance (A...
(Date:8/28/2008)...cord minimum ice cover in the Arctic, current obse... the extent of polar sea-ice may again shrink to a...t observations from mid-August depict that a new r...a matter of weeks. The animation above is a series...s acquired between early June and mid-August 2008 ...
(Date:8/28/2008)...pecial discretionary prize as part of the 2008 Eur...for Communication in the Life Sciences. The award...ic communication activity on a single organism usi...e Springer book The Buzz About Bees, a fascinating...olonies. , The Buzz about Bees features over 200...
Breaking Biology News(10 mins):Biophysical method may help to recover hearing 2National security remedies among topics at surveillance confab 2National security remedies among topics at surveillance confab 3Arctic ice on the verge of another all-time low 2Arctic ice on the verge of another all-time low 3Springer bee expert Juergen Tautz wins prize for public communication 2Cosmetic Surgery for Men in New Jersey is Seeing a Dramatic Increase at Parker Center for Plastic Surgery 23666 1Cosmetic Surgery for Men in New Jersey is Seeing a Dramatic Increase at Parker Center for Plastic Surgery 23666 2Cosmetic Surgery for Men in New Jersey is Seeing a Dramatic Increase at Parker Center for Plastic Surgery 23666 3CMP is Back This Year with Loads of Innovative Ideas and Varieties of Food Ingredients 23661 1CMP is Back This Year with Loads of Innovative Ideas and Varieties of Food Ingredients 23661 2Cadaver tissue fails nearly 25 percent of the time in young ACL reconstructions 23658 1Cadaver tissue fails nearly 25 percent of the time in young ACL reconstructions 23658 2A short and sweet diagnosis for cancer 3F 23656 1A short and sweet diagnosis for cancer 3F 23656 2
...p with ways to repair the human body, replacing de... and ceramic substitutes ?but the body does not al... from Brown and Purdue universities have found tha...can dramatically change the way cells colonize a w...s have focused on the materials used in stents ?th...
...o the cells of blood vessels running through ovari...ne day improve screening, diagnosis and treatment ...he University of Michigan, University of Pennsylva...laser technique to isolate blood vessel cells from...samples. From there, they were able to determine w...
...of way to ensure they mate with only the highest r...nd physical characteristics that their offspring m...umoto-Oda from the Department of Welfare and Cultu...zees do not synchronize their reproductive activit...able males to coerce them into mating. The findin...
...l College of Veterinary Medicine (VMRCVM) at Virgi... variant of Avian Newcastle disease virus (NDV) ca...n Subbiah, assistant professor in the Department o...d a prestigious research grant by the Department o...Research Program?award will support the exploratio...
Other Biology News:Nanotextured implant materials: blending in, not fighting back 2Nanotextured implant materials: blending in, not fighting back 3Researchers identify ovarian cancer biomarkers 2Female chimps keep the bullies at bay 2Veterinary scientists explore poultry virus as cancer killer 2
...of the LVF-UV-HL, LVF-CUV-ADP, FHS-LVF and CVD-Dif...w-pass Linear Variable Filters to create the world...velength and adjustable bandpass. Each filter feat...cking band (99.8%). These filters -- with interfe...
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals .
Ms anti-Cyclophilin D
Intended to qualitatively detect EGFR gene amplification in formalin-fixed, paraffin-embedded (FFPE) tissue sections, metaphase chromosome spreads, and cell preparations, using Chromogenic In Situ Hy
Biology Products: